The UK market for Penicillins and Streptomycins in dosage form has shown a decline from 2013 to 2023, decreasing from $891.05 million to $730 million. Between 2022 and 2023, there was a 1.31% reduction, following a significant decrease of 10.29% the previous year. The compound annual growth rate (CAGR) over the last five years was -1.45%, reflecting a trend of contraction in the market.
Future trends to watch for include:
- Potential market stabilization due to healthcare policy changes.
- Opportunities for generic drug growth amidst pricing pressures.
- Innovation in antibiotic treatments to combat resistance could spur demand.
How does the United Kingdom rank in Penicillins and Streptomycins in Dosage Market Size Value?
| # | 33 Countries | US Dollars | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 United States | 4,303,400,000 | 2023 | +0.61% | +1.48% | View data |
| 2 | 2 United Kingdom | 730,000,000 | 2023 | -1.31% | -1.45% | |
| 3 | 3 France | 717,200,000 | 2023 | -1.91% | +0.034% | View data |
| 4 | 4 Italy | 622,330,000 | 2023 | -3.96% | -4.86% | View data |
| 5 | 5 Germany | 476,270,000 | 2023 | +1.03% | +1.1% | View data |
